

ANNUAL REPORT

2013

AMERICAN ASSOCIATION FOR
THE STUDY OF LIVER DISEASES



www.aasld.org

VISION:

To Prevent and Cure Liver Disease

MISSION:

To advance and disseminate
the science and practice of
hepatology, and to promote liver
health and quality patient care.

American Association for the Study of Liver Diseases

2013 Annual Report

AWARD RECIPIENTS:

2013 Research and Career Development Awards.....	2
2013 AASLD Abstract Awards	5
2013 Distinguished Award Recipients	8
2013 AASLD Emerging Liver Scholar Resident Travel Award Program	10

TRAIN/EDUCATE:

New Developments in Transplant Hepatology Training	11
American Board of Internal Medicine (ABIM).....	11
The Liver Meeting®.....	11
Special Interest Groups (SIGs)	14
Single Topic Conferences	14
Digestive Disease Week	15
LiverLearning®	15
AASLD Curriculum & Training (ACT)	15
ACT-on-HCV.....	15
Collaboration	16
Journals	17
Clinical Practice Guidelines	17
Online Expert Advice for Clinicians Treating Hepatitis C.....	18

EFFECT:

Public Policy	19
---------------------	----

FINANCIALS

Financials	22
------------------	----

GOVERNANCE:

Governing Board	24
Past Presidents.....	25
AASLD Staff	26

2013 RESEARCH AND CAREER DEVELOPMENT AWARDS

The AASLD Research, Career Development, and Abstract Awards are the preeminent awards for liver research and advanced hepatology training. In 2013, AASLD and The AASLD Liver Research Fund committed over \$2.4 million in funding for awards and fellowships. This level of funding represents the largest single commitment in support of liver research and advanced hepatology training by any professional organization.

AASLD and the AASLD Liver Research Fund are able to provide funding at a critical time in the careers of young investigators and other healthcare providers, which may encourage them to pursue careers in hepatology. We support three types of Awards:

- **Multi-Year Research Awards** in Basic, Clinical, and Translational Research
- **One-Year Career Development Awards** to encourage front-line providers to pursue specialized training in hepatology
- **Abstract Awards** which allow young investigators the opportunity to present their outstanding research to an international audience at The Liver Meeting®

The AASLD awards program has a proven track record of success. Since 2000, AASLD has funded over \$32 million in awards.

AASLD Liver Scholar Award

A three-year basic science award of \$225,000 (\$75,000/year) that is designed to bridge the gap between completion of research training and attaining status as an independent research scientist and encourage young investigators to pursue a career in liver-related research. The additional research experience provided by this award enables young researchers to successfully compete for research grants from national sources, particularly the National Institutes of Health (NIH).

Baran A. Ersoy, PhD

Brigham and Women's Hospital
Boston, MA

MENTOR: David Cohen, MD, PhD

RESEARCH PROJECT: *Molecular control of hepatic insulin signaling by phosphatidylcholine transfer protein*

Cara T. Pager, PhD

University at Albany, State University of New York
Albany, NY

MENTOR: Peter Ells, MD

RESEARCH PROJECT: *The Role of RCK/p54 in hepatitis C virus gene expression*

Leela L. Paris, PhD

Indiana University
Indianapolis, IN

MENTOR: A. Joseph Tector, PhD

RESEARCH PROJECT: *The study of SIRP and ASGR1 in platelet phagocytosis by the porcine liver*

Wei Qiu, PhD

Loyola University Chicago
Chicago, IL

MENTOR: Tarun Patel, PhD

RESEARCH PROJECT: *Repress HCC development by inhibiting PUMA*

AASLD gratefully acknowledges funding for the 2013 Liver Scholars from AbbVie, Genentech, Merck, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.



2013 Liver Scholar Awards Recipients

AASLD/Alpha-1 Foundation Liver Scholar Award

A three-year basic science award of \$225,000 (\$75,000/year) with a focus on alpha-1-antitrypsin deficiency-associated liver disease.

This award was established in recognition of the 50th anniversary of the discovery of Alpha-1 Antitrypsin Deficiency.

Andrew Chu, MD

Children's Hospital of Pittsburgh of UPMC
Pittsburgh, PA

MENTOR: David Perlmutter, MD

RESEARCH PROJECT: *Mechanisms of action for autophagy enhancer drugs on alpha-1-antitrypsin deficiency-associated liver disease*

AASLD gratefully acknowledges funding for the 2013 AASLD/Alpha-1 Liver Scholar Award from Alpha-1 Foundation, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

AASLD Career Development in Liver Transplantation

In Memory of the University of Michigan Transplant Team

A two-year award of \$90,000 (\$45,000/year) designed to foster career development for an individual performing clinical and/or translational research in the field of liver transplantation and who has shown commitment to excellence in the field at an early stage in their career.

This award was established to honor the Transplant Survival Flight Team whose transport crashed over Lake Michigan on June 4, 2007 on the return leg of an organ procurement mission. This award honors those dedicated to life-saving organ transplantation.

Michael G. Hughes, Jr., MD

University of Louisville School of Medicine
Louisville, KY

MENTOR: Craig J. McClain, MD

RESEARCH PROJECT: *Role of Envelope Protein Glycosylation Sites in Hepatitis C Viral Infection of Liver Allografts*

AASLD gratefully acknowledges funding for the 2013 Clinical and Translational Research Award from Astellas USA Foundation and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

AASLD Sheila Sherlock Clinical and Translational Research Award in Liver Diseases

This two-year clinical research and/or translational research award of \$150,000 (\$75,000/year) is intended to foster career development for young investigators performing clinical and/or translational research in a liver-related area who have shown commitment to excellence at an early stage in their research study.

This award is named in honor of Dame Sheila Sherlock for her pioneering research and dedication to young research fellows which helped elevate hepatology to the discipline it is today.

Monika A. Sarkar, MD, MAS

University of California, San Francisco
San Francisco, CA

MENTOR: Marion Peters, MD

RESEARCH PROJECT: *Racial/ethnic Differences in Fibrosis Progression in HIV/HCV Co-Infected Women*

AASLD gratefully acknowledges funding for the 2013 Sheila Sherlock Clinical and Translational Research Award from Genentech and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

AASLD Clinical and Translational Research Award in Liver Diseases

This two-year clinical research and/or translational research award of \$150,000 (\$75,000/year) is intended to foster career development for young investigators performing clinical and/or translational research in a liver-related area who have shown commitment to excellence at an early stage in their research study.

Brittany N. Bohinc, MD

Duke University
Durham, NC

MENTORS: Anna Mae Diehl, MD, and Manal Abdelmalek, MD, MPH

RESEARCH PROJECT: *Non-Alcoholic Fatty Liver Disease Is Associated With Systemic and Hepatic Hypothyroidism*

AASLD gratefully acknowledges funding for the 2013 Clinical and Translational Research Award from Merck and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

AASLD Advanced/Transplant Hepatology Fellowship

Provides \$60,000 in salary and benefit support for gastroenterology (GI) fellows pursuing an additional full-year of training focused on patient care in advanced/transplant hepatology. The intent of the program is to prepare the trainees to be eligible for certification in transplant hepatology by the American Board of Internal Medicine (ABIM) and/or the American Board of Pediatrics (ABP).

Monique L. Choquette, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
MENTOR: John Bucuvalas, MD

Matthew G. Deneke, MD
Mayo Clinic in Rochester
Rochester, MN
MENTOR: Kymberly Watt, MD

Chanda K. Ho, MD, MPH
University of California, San Francisco
San Francisco, CA
MENTOR: Norah Terrault, MD, MPH



2013 Advanced Hepatology Awards Recipients

Christine C. Hsu, MD
Columbia University
New York, NY
MENTOR: Robert Brown, MD, MPH

Brian Kim, MD
Mount Sinai School of Medicine
New York, NY
MENTOR: Thomas Schiano, MD

Ming Valerie Lin, MD
Massachusetts General Hospital
Boston, MA
MENTOR: Raymond T. Chung, MD

Marina Serper, MD
Hospital of the University of Pennsylvania
Philadelphia, PA
MENTOR: K. Rajender Reddy, MD



2013 NP/PA Recipients

Jennifer M. Vittorio, MD
Columbia University
New York, NY
MENTOR: Joel Lavine, MD, PhD

AASLD gratefully acknowledges funding for the 2013 Advanced/Transplant Hepatology Fellowship Program from AbbVie, Astellas USA Foundation, Gilead Sciences, Merck, Janssen Pharmaceutical Companies, Salix Pharmaceuticals, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

AASLD NP/PA Clinical Hepatology Fellowship

Provides \$78,000 in salary and benefit support for certified and licensed physician assistants (PA) or nurse practitioners (NP) pursuing a full year of training focused on clinical care in hepatology. This award is designed to increase the number of associate practitioners in clinical hepatology; thereby increasing access for liver disease patients to well-trained clinicians.

Danielle E. Cardona, PA-C
The University of North Carolina at Chapel Hill
Chapel Hill, NC
MENTOR: Jama M. Darling, MD

Melissa Ferrari, PA-C
Hospital of the University of Pennsylvania
Philadelphia, PA
MENTOR: K. Rajender Reddy, MD

Ann E. (Hagan) Burke, CRNP, FNP-BC
Thomas Jefferson University
Philadelphia, PA
MENTOR: Steven K. Herrine, MD

Melissa R. Laycock, APRN, FNP-BC
Kansas University Medical Center
Kansas City, KS
MENTOR: Richard K. Gilroy, MD

Jordan Mayberry, PA-C
UT Southwestern Medical Center
Dallas, TX
MENTOR: William Lee, MD

AASLD gratefully acknowledges funding for the 2013 NP/PA Clinical Hepatology Fellowship Program from Janssen Pharmaceuticals, Salix Pharmaceuticals, Vertex Pharmaceuticals, and donors to the New Challenges-New Solutions Campaign and The AASLD Liver Research Fund.

2013 AASLD Abstract Awards

Fellow Research Award

A \$1,000 award presented for the best abstract submitted to The Liver Meeting® by a fellow.

Alexandra Menchise, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
ABSTRACT TITLE: *Heterozygosity for deleterious mutations in Abcb4 is associated with a pro-inflammatory hepatic transcriptome predisposing neonatal mice to cholestatic liver injury*

AASLD gratefully acknowledges funding for the 2013 Fellow Research Award is made possible through a grant from the SunTrust Foundation.

Pediatric Research Award

A \$1,000 award presented for the best abstract submitted to The Liver Meeting® by a physician/scientist with a primary appointment affiliation in a department of pediatrics.

Alexander Wree, MD
University of California, San Diego
San Diego, CA
ABSTRACT TITLE: *NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis*

AASLD gratefully acknowledges funding for the 2013 Pediatric Research Award is made possible through a grant from the SunTrust Foundation.

Resident Research Award

The purpose of this \$1,000 award is to recognize high quality research undertaken by a resident in training. The recipient must be a primary contributor on the project and committed to a career in liver disease.

Phillip Levine, MDCM
Scott & White Hospital, Texas A&M
HSC College of Medicine
Temple, TX
ABSTRACT TITLE: *The role of stem cell derived microvesicles and microRNAs during alcoholic liver injury*

Student Research Award

A \$1,000 award presented for research conducted by a graduate or undergraduate student. The recipient must be a primary contributor on the project.

Camilla Pilati, PhD
INSERM U674
Paris, France
ABSTRACT TITLE: *Integrative genomic profiling of hepatocellular adenomas identify mutational processes involved in malignant transformation*

AASLD gratefully acknowledges funding for the 2013 Student Research Award is made possible through a grant from the SunTrust Foundation.

PSC Partners Seeking a Cure Award

A \$3,000 award presented to the investigator presenting the most promising PSC research at The Liver Meeting®.

James H. Tabibian, MD
Mayo Clinic in Rochester
Rochester, MN
ABSTRACT TITLE: *Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis*

AASLD gratefully acknowledges funding for the 2013 PSC Partners Seeking a Cure Award from PSC Partners.



2013 AASLD Abstract Awards Recipients

Liver Transplant and/or Hepatobiliary Surgery Award

These \$1,000 travel awards enable liver transplant and/or hepatobiliary surgery fellows submitting abstracts for The Liver Meeting® to receive travel support.

Christoph Tschuor, MD
University Hospital Zurich
Zurich, Switzerland
ABSTRACT TITLE: *Activation of the Constitutive Androstane Receptor (CAR) reverses deficient liver regeneration in the Small-For-Size Syndrome via Foxm1b and miR375/YAP-dependent pathways*

Federico Piñero Fernandez Casares, MD
Hospital Universitario Austral
Buenos Aires, Argentina
ABSTRACT TITLE: *Risk Factors of Neurologic Events after Liver Transplantation: Towards a Prognostic Risk Score Assessment*

AASLD gratefully acknowledges funding for the 2013 Liver Transplant and/or Hepatobiliary Surgery Award is made possible through a grant from Ikaria.

Edmund J. Bini, MD Travel Award

This \$2,500 memorial travel award was established to honor Dr. Edmund Bini’s outstanding career as a clinician and researcher. The award is presented to a fellow or junior investigator who submits the most outstanding abstract on clinical hepatitis C research for The Liver Meeting®.

Partha Chandra, PhD
Tulane University Health Sciences Center
New Orleans, LA
ABSTRACT TITLE: *Persistently Infected Hepatitis C Virus Cell Culture Impairs Type I But Not The Type III IFN Signaling*
AASLD gratefully acknowledges the donors to the AASLD Liver Research Fund whose gifts support funding for the 2013 Dr. Edmund J. Bini Travel Award.

Professor Margit Hamosh Travel Award

This \$2,500 memorial travel award was established to honor the memory of Dr. Margit Hamosh’s life and legacy. The award is presented to a fellow or junior investigator who submits the most outstanding abstract on hepatocellular carcinoma research for The Liver Meeting®.

Tsunekazu Oikawa, MD, PhD
UNC Lineberger Comprehensive Cancer Center of the University of North Carolina School of Medicine
Chapel Hill, NC
ABSTRACT TITLE: *Human Fibrolamellar Hepatocellular Carcinomas: Evidence for their Derivation from Biliary Tree Stem Cell Subpopulations*
AASLD gratefully acknowledges the donors to the AASLD Liver Research Fund whose gifts support funding for the 2013 Professor Margit Hamosh Travel Award.



2013 Young Investigator Travel Awards Recipients

Young Investigator Travel Awards

These \$500 travel awards enable young investigators submitting abstracts for The Liver Meeting® to receive travel support.

Hawwa Alao, MD
National Institutes of Health
Bethesda, MD
ABSTRACT TITLE: *Global microRNA profiling reveals complex interactions among hepatic microRNA regulation, hepatitis C virus infection and interferon response*

Cristina Cudalbu, PhD
École Polytechnique Fédérale De Lausanne (EPFL)
Lausanne, Switzerland
ABSTRACT TITLE: *In vivo brain energy metabolism in a rat model of chronic Hepatic Encephalopathy using 31P MRS*

Ramy El-Diwany
Johns Hopkins School of Medicine
Baltimore, MD
ABSTRACT TITLE: *Acute Hepatitis C Infection is Associated with an Increase in Circulating microRNA-122*

Gene Im, MD
Mount Sinai School of Medicine
New York, NY
ABSTRACT TITLE: *Initial Single-Center Experience in the United States with Early Liver Transplantation for Severe Alcoholic Hepatitis*

Davide Povero, PhD
University of California, San Diego
San Diego, CA
ABSTRACT TITLE: *Hepatocytes-derived microparticles released during lipotoxicity induce hepatic stellate cells activation and migration*

Yoon Seok Roh, DVM, PhD
University of California, San Diego
San Diego, CA
ABSTRACT TITLE: *Hepatocyte gp130-mediated Signaling promotes hepatocellular carcinogenesis through activation of mTORC1 and Stat3*

Barry Schlansky, MD, MPH
Oregon Health & Science University
Portland, OR
ABSTRACT TITLE: *Wait List Time Predicts Survival after Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study in the UNOS Registry*

Soona Shin, PhD, MS
University of Pennsylvania
Philadelphia, PA
ABSTRACT TITLE: *The Role of Keap1/Nrf2 in Modulating Redox Status of Hepatic Progenitor Cells*

Irina Tikhanovich, PhD
Kansas University Medical Center
Kansas City, KS
ABSTRACT TITLE: *Hepatitis C induced inhibition of arginine methylation activates antioxidant functions of the FOXO3 transcription factor through the ubiquitin hydrolase USP7*

Laura Wozniak, MD, MS
University of California, Los Angeles
Los Angeles, CA
ABSTRACT TITLE: *Complement Binding Donor Specific Antibodies are Associated with Late Graft Dysfunction Following Pediatric Liver Transplantation*

AASLD acknowledges funding for the 2013 Young Investigator Travel Awards is made possible through an independent grant from Merck.

Midlevel Professional Awards

These \$500 awards are presented for the best abstracts submitted to The Liver Meeting® by an associate member.

Geri Hirsch, NP
Capital District Health Authority
Halifax, Canada
ABSTRACT TITLE: *Canadian Experience Developing Viral Hepatitis Nursing Standards and Competencies*

Amy Nelson, BSN, RN, ACRN
National Institute of Allergy and Infectious Diseases/ National Institutes of Health
Bethesda, MD
ABSTRACT TITLE: *Impact of Pre-existing Mental Health Disorders on Adherence and Sustained Virologic Response with an Interferon-Free Trial of Sofosbuvir and Ribavirin for Chronic Hepatitis C*



2013 AASLD Midlevel Professional Awards Recipients

2013 DISTINGUISHED AWARD RECIPIENTS

AASLD Distinguished Achievement Award

The AASLD Distinguished Achievement Award is given to an individual in honor of his or her sustained scientific contributions to the field of liver disease and the scientific foundations of hepatology. The award honors a sustained contribution rather than a single discovery or major achievement. The awardee need not be a member of AASLD and may be a non-scientist but the contribution should be solidly in the area of liver disease, physiology, anatomy or pathology.

Professor Roger Williams, CBE, MD, FRCP, FRCS, FRCPE, FRACP, FMedSci, FRCPI (Hon), FACP (Hon)

Foundation for Liver Research
London, United Kingdom



Prof. Williams' career in hepatology began in 1959 when he was appointed as Lecturer in Medicine at the Royal Free Hospital by the late Professor Dame Sheila Sherlock. He worked at King's College London from 1966 to 1996 where he established the

Institute of Liver Studies and served as its first Director. In 1968 he was involved in the first liver transplant in the United Kingdom.

In 1973 he created the Foundation for Liver Research which has become the United Kingdom's leading gastroenterological charity. In 1996 he moved to University College London where he established and directed the Institute of Hepatology.

He has published over 2,500 papers, journals and books and served on over 20 editorial boards. He is a Fellow of the Academy of Medical Sciences and is the recipient of numerous honorary fellowships and awards including the Gold Medal of the Canadian Liver Foundation (1992), the American Society of Transplantation Senior Achievement Award (2004), the Hans Popper Lifetime Achievement Award (2008) and the Distinguished Service Award of the International Liver Transplant Society (2011).

His main clinical and research interests are in acute liver failure and liver transplantation.

AASLD Distinguished Service Award

The AASLD Distinguished Service Award is given to an individual in honor of his or her sustained service to AASLD or the liver disease community in general. The award recognizes service provided to the community of hepatology researchers and clinicians over an extended period; service that is well above and beyond that provided by many members who serve on the Governing Board and Committees of AASLD. The awardee need not be a member of AASLD.

Frederick J. Suchy, MD

University of Colorado School of Medicine
Aurora, CO



Frederick J. Suchy, MD graduated from the University of Cincinnati College of Medicine in 1974. He completed pediatric residency and fellowship training in pediatric gastroenterology and hepatology at Cincinnati Children's Hospital Medical Center with Drs. William K.

Schubert and William F. Balistreri. He subsequently was Chief of Pediatric Gastroenterology and Hepatology at Yale University (1988-1996) and Chair of Pediatrics at Mount Sinai School of Medicine (1996-2009).

Dr. Suchy has contributed to the AASLD and the hepatology community in many capacities including memberships on the Research Committee, the Education Committee, several Strategic Planning Committees, and search committees for the AASLD executive director and an editor for *HEPATOLOGY*. He was elected to the AASLD governing board (1999-2004), and served as President in 2003. He has chaired the Scientific Advisory Committee for Pediatric Liver Diseases of the American Liver Foundation, and was the Vice Chair for Scientific Affairs, National Board of Directors, American Liver Foundation (2006-2010).

Dr. Suchy's research has been funded by the National Institutes of Health for over three decades. The focus of his work has been on the biology and pathobiology of liver transport systems that contribute to bile formation. He has also had a long-standing clinical focus on pediatric liver disease, and in addition to publication of many reviews, case reports, and book chapters, he is an editor of a comprehensive textbook entitled "Liver Disease in Children" which is now in its 4th edition.


Dr. Suchy is currently Chief Research Officer, Director of The Children's Hospital Colorado Research Institute, Professor of Pediatrics and Associate Dean for Child Health Research, University of Colorado School of Medicine, Aurora, CO.

AASLD Distinguished Clinician Educator/Mentor Award

The Distinguished Clinician Educator/Mentor Award is given in honor of the sustained service of clinician educators to AASLD or the liver community in general. The award recognizes the skills of outstanding clinicians and educators who have made momentous contributions to hepatology over an extended period. The awardee need not be a member of AASLD.

Arthur J. McCullough, MD

Digestive Disease Institute at the Cleveland Clinic
Cleveland, OH



Arthur J. McCullough, MD, received his MD degree from the State University of New York (SUNY) at Syracuse in 1974. After his internal medicine and chief medical residency at the Cleveland Clinic in Cleveland, OH, Dr. McCullough briefly considered a career in cardiology before becoming a G.I. fellow at the Mayo Clinic in Rochester, MN. While there, he earned the prestigious J. Arnold Bargen Award for clinical, research, and teaching excellence.

He returned to Cleveland in 1980 and became a Professor of Medicine at Case Western Reserve School of Medicine and a gastroenterologist at MetroHealth Medical Center, where he became Division Chief in 1991. In 2006, he took the position of Chairman of the Cleveland Clinic Department of Gastroenterology and Hepatology and Professor of the Lerner College of Medicine of Case Western Reserve and Vice Chairman for research and education for the Digestive Disease Institute. He is currently the director of research for the Digestive Disease Institute at the Cleveland Clinic.

Over his career, Dr. McCullough has received multiple institutional teaching awards, motivated numerous young physicians, and maintained a clinical excellence enthusiastically endorsed by his patients. He has been named one of the Best Doctors in America and one of the top 75 gastroenterologists in the country, co-authored two books on nonalcoholic fatty liver disease and chaired NIH-funded research on fatty liver disease. Dr. McCullough has received research and achievement awards from the American Diabetes Association, the Cleveland Foundation and the American Liver Foundation, and served as president of the American Association for the Study of Liver Diseases in 2008.

Dr. McCullough's primary research interests include the study of non-alcoholic steatohepatitis and alcoholic steatohepatitis, abnormal energy and protein metabolism in cirrhosis, and nutritional and pharmacologic strategies to address malnutrition in chronic liver disease. He is a leader in research of nonalcoholic fatty liver disease, a disease that affects nearly all fields of clinical medicine and is the most common form of chronic liver disease in the United States.

2013 AASLD Emerging Liver Scholar Resident Travel Award Program

- Ahmed Akhter, MD
University of Wisconsin
Hospital and Clinics
MENTOR: Adnan Said, MD

Pranab M. Barman, MD
University of Michigan Health System
MENTOR: Grace Su, MD

Jihane N. Benhammou, MD
University of California, Los Angeles
MENTOR: Simon Beaven, MD

Ruchi Bhatia, MA
Saint Louis University Hospital
MENTOR: Brent Tetri, MD

Kristin E. Burke, MD
Beth Israel Deaconess Medical Center
MENTOR: Simon Robson, MD

David T. Chao, MD
University of Pittsburgh Medical Center
MENTOR: Mindie Nguyen, MD

Cynthia E. Cherfane, MD
University of Iowa Hospitals and Clinics
MENTOR: Michael Voigt, MD

Jacqueline J. Choi, MD
University of Illinois at Chicago
Medical Center
MENTOR: Grace Guzman, MD

Doan Y. Dao, MD
The University of Texas Southwestern
Medical Center
MENTOR: William M. Lee, MD

Nicholas J. Day, MD
University of Michigan
MENTOR: Anna Suk-Fong Lok, MD

Albert Do, MD
Yale-New Haven Hospital
MENTOR: Guadalupe Garcia-Tsao, MD

Mohannad F. Dugum, MD
Cleveland Clinic Foundation
MENTOR: Nizar Zein, MD

Moria B. Hilscher, MD
Mayo School of Graduate
Medical Education
MENTOR: Vijay Shah, MD

- Neha R. Jakhete, MD
Johns Hopkins Hospital
MENTOR: Ayman Koteish, MD

Daniel Joyce, MD
Cleveland Clinic
MENTOR: John J. Fung, MD

Rachel Kohn, MD
Massachusetts General Hospital
MENTOR: Parsia A. Vagefi, MD

Jeffrey P. LaFond, MD
University of Virginia
MENTOR: Neeral Shah, MD

Christina C. Lindenmeyer, MD
Thomas Jefferson University Hospital
MENTOR: Jonathan M. Fenkel, MD

Lisa M. McElroy, MD
Northwestern University
MENTOR: Daniela P. Ladner, MD

Adam Mikolajczyk, MD
The University of Chicago
MENTOR: Andrew Aronsohn, MD

John T. Miura, MD
Medical College of Wisconsin
MENTOR: T. Clark Gamblin, MD

Omar Y. Mousa, MD
SUNY—Upstate Medical University
MENTOR: Victor Ankoma-Sey, MD

Nirah S. Patel, MD
University of California at San Diego
Medical Center
MENTOR: Rohit Loomba, MD

- Joshua R. Peck, MD
Wexner Medical Center at The Ohio
State University
MENTOR: Jim Hanje, MD

Joseph Roberts, MD
University of Colorado Anschutz
Medical Campus
MENTOR: Kiran Bambha, MD

Nitzan C. Roth, MD
University of California Los Angeles
MENTOR: Neil Kaplowitz, MD

Suzanne R. Sharpton, MD
University of California San Francisco
MENTOR: Oren Fix, MD

Shazia M. Siddique, MD
Johns Hopkins Hospital
MENTOR: James Hamilton, MD

Amber L. Tierney, MD
Washington University/
Barnes-Jewish Hospital
MENTOR: Kevin Korenblat, MD

Nicole M. Welch, MD
University of Chicago
MENTOR: Nancy Reau, MD

Ju Dong Yang, MD
University of Arkansas for Medical
Sciences/Mayo Clinic
MENTOR: Lewis R. Roberts, MD

Elizabeth X. Zheng, MD
Albert Einstein College of Medicine/
Montefiore Medical Center
MENTOR: Allan Wolkoff, MD



2013 Emerging Liver Scholar Resident Travel Award Recipients

TRAIN/EDUCATE

New Developments in Transplant Hepatology Training: Milestones, EPAs and the In-training Examination

2013 marked many important changes in graduate medical education. The Accreditation Council for Graduate Medical Education (ACGME) introduced the next phase of competency-based training for residency and fellowship programs, called the Next Accreditation System (NAS). Of the key NAS performance indicators, much of the current focus is on milestones. AASLD participated in the development of the subspecialty reporting milestones, which are modeled closely on the Internal Medicine reporting milestones. AASLD was a key participant in the development of Entrustable Professional Activities (EPAs) for Gastroenterology training, which includes the necessary development of competency in general hepatology.

American Board of Internal Medicine (ABIM)

AASLD collaborated with ABIM in 2012 to create a three-year competency-based pilot program in gastroenterology-transplant hepatology training. Now in its second year, the pilot program is a qualitative success in the use of competency-based training concepts, while also effectively reducing the length of training required to become a board-certified Transplant Hepatologist.

The Liver Meeting® 2013—Science, Technology and Collaboration

The Liver Meeting® was designed specifically to educate researchers and clinicians on the dynamic changes in the field of hepatology, to connect leading scientists from around the world, and to incorporate technological solutions to enhance the attendee experience.

During our first ever meeting in Washington, DC, more than 8,800 health professionals from 96 countries met to exchange groundbreaking research and progressive clinical treatments in liver disease. In addition to the educational sessions, the exhibit hall provided attendees the opportunity to further their awareness of products and services available to them. More than 1,000 exhibit staff representing 83 companies including industry, publishing, non-profit organizations and more were on hand to interact with attendees.

Expanding on the in-person experience, AASLD offered a meeting app which included all accepted abstracts, ePosters, LiverLearning®, and, for the first time, a livestream webcast of the Hepatitis

Debrief. ePosters allow an attendee to interact with the poster presenters virtually to extend the poster hall experience. LiverLearning®—available to all registrants of the meeting and AASLD members—hosts a number of sessions captured during the meeting for on-demand viewing. Our Twitter feed was also streamed into the general session room keeping attendees in the loop on the meeting chatter.

The Liver Meeting® 2013 attendance, scores, evaluations and comments reflect a meeting that is maintaining its credibility and increasing its popularity within the hepatology community. The Liver Meeting® 2014 will be in Boston, Massachusetts.


Postgraduate Course

The AASLD Postgraduate Course on *New Treatments in Liver Disease: A New Era of Diagnostics, Therapeutics and Intervention in Hepatology*; Course Directors: Adrian M. Di Bisceglie, MD and Paul Martin, MD highlighted significant issues of liver research facing physicians today. This course provided 3,200 learners with a comprehensive overview of the state-of-the-art advances in the management of chronic liver diseases based on the latest in both basic and clinical research.

Scientific and Educational Activities at The Liver Meeting®

AASLD offers scientific educational activities that are developed by leading hepatologists. Each activity features expert speakers presenting the finest data in the most current and critical topics of liver disease.

More than 3,100 abstracts were submitted. 72% were accepted for oral and poster presentation with 203 receiving recognition as a Poster of Distinction. Thirty-nine scientific sessions were conducted to present the most up-to-date research available in the field. The oral sessions were complemented by more than 40 interactive posters sessions. AASLD activities meet the increasing demand



of hepatology's growing importance as a medical specialty by providing participants the opportunity to exchange research, discuss outcomes, and interact with colleagues focused on liver and biliary diseases.

Invited Lectures at The Liver Meeting®

The offering of groundbreaking research by top scientists in their specific areas of hepatobiliary research continued to be a priority. The lectures featured:

Global Forum

The global forum focused on the world-wide public health epidemic of liver diseases caused by excessive alcohol use or obesity and the metabolic syndrome. The aim of this program was to develop a discussion on this topic among the five major regions of the world, North America, Europe, Latin America, Asia, and Africa. The discussion addressed the most important public health problems regarding fatty liver diseases in each of these regions.

Hepatitis Debrief

This session provided a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting® 2013. Attendees left this session with practical knowledge of cutting-edge therapies for chronic hepatitis C. Additionally, for the first time, this program was live streamed to allow participation by those who could not attend in person.

Hans Popper Basic Science State-of-the-Art Lecture

In his lecture titled *Alpha-1 Antitrypsin Deficiency: Novel Treatment Strategies Fifty Years After Discovery*, David Perlmutter, MD, described the history of the disease, what we have learned about its unique clinical sequelae and novel treatment strategies that originated from understanding the unique pathobiology.

This annual lecture recognizes Dr. Popper, the founder of the American Association for the Study of Liver Diseases (AASLD), for his role in the establishment of HEPATOLOGY and his promotion of the intellectual spirit of the Association.

Leon Schiff State-of-the-Art Lecture

HCV Therapeutics in the Post-Interferon Era: More than the Sum of its Parts? delivered by Robert Schooley, MD, discussed the role of innate immune evasion mechanisms of HCV in establishing and maintaining chronic infection in the liver, and identified the potential implications of viral dynamics and replication fidelity as barriers to the pharmacologic cure of HCV infection.

This annual lecture recognizes Dr. Schiff's work to elevate the study and practice of hepatology to the discipline it is today. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges the National Genetics Institute for their generous support of this program.

Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture

Anthony Atala, MD, delivered his lecture on *Regenerative Medicine: New Approaches to Healthcare* that described the field of tissue engineering and regenerative medicine, and explained current research and clinical applications in regenerative medicine.

This annual lecture recognizes the pioneering work that Dr. Starzl has done to elevate liver transplantation from an experimental procedure

to one that saves thousands of lives annually. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges the donors to this fund, which includes Astellas USA, for their support.

Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

William Lee, MD, delivered a lecture titled *Acetaminophen and the Liver: Poison or Panacea?* that focused on possible reasons for this persistent challenge and areas to explore for future remediation of the problem.

The annual presentation of this lecture continues to recognize Dr. Zimmerman's contributions to the field by providing valuable insights on liver toxicity and injury. A restricted fund has been established to support the lecture in perpetuity and AASLD gratefully acknowledges Eli Lilly and Company for their generous support of this program.

President's Choice Lecture

The President's Choice lecture, *Random Germline Mutagenesis in the Analysis of Immunity*, delivered by Nobel Laureate Bruce Beutler, MD, described how a classical genetic approach can be used to provide a list of the causes of inherited disease and how it has become practical to saturate the genome of the mouse with mutations and assign cause and effect.



Special Interest Groups (SIGs)

Expanding on the existing 12 SIGs, the Governing Board approved the creation of a Clinical Practice SIG in 2013 to address the needs of AASLD members in the clinical community. Their mission is in development with full formation of the group expected by the end of 2014.

At The Liver Meeting® 2013, two of the six programs developed and presented by SIGs were collaborations by multiple SIGs and the Liver Transplantation and Surgery SIG introduced a poster tour mentorship program. There are currently 2,755 SIG members that participate in the following groups:

- | | |
|---|--|
| • Acute on Chronic Liver Failure
CHAIR: Jasmohan Bajaj, MD | • Liver Cell Biology in Hepatic Disease
CHAIR: Mark A. McNiven, PhD |
| • Cholestatic Liver Disorders
CHAIR: Saul J. Karpen, MD, PhD | • Liver Fibrosis
CHAIR: Natalie Torok, MD |
| • Hepatitis B
CHAIR: Brian J. McMahon, MD | • Liver Transplantation and Surgery
CHAIR: David C. Mulligan, MD |
| • Hepatitis C
CHAIR: Michael W. Fried, MD | • Pediatric Liver Disorders
CHAIR: Regino Gonzalez-Peralta, MD |
| • Hepatobiliary Neoplasia
CHAIR: Gregory J. Gores, MD | • Portal Hypertension
CHAIR: Guadalupe Garcia-Tsao, MD |
| • Hepatotoxicity
CHAIR: Robert J. Fontana, MD | • Steatosis and Steatohepatitis
CHAIR: Naga P. Chalasani, MD |

Single Topic Conferences

In 2013, three Single Topic Conferences (STC), one Emerging Trends Conference (ETC) and the AASLD/FDA Workshop were conducted.

1. Clinical Research STC: Portal Hypertension and Variceal Hemorrhage
2. Basic Research STC: Portal Hypertension and Vascular Biology of the Liver
3. Hepatitis STC: Hepatitis C Treatment in Special Populations
4. ETC: Reactivation of Hepatitis B
5. AASLD/FDA Workshop: Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease

Attendee evaluations suggested these conferences meet their objectives, provide excellent interactions and produce new research collaborations.

Of special note, the ETC on Reactivation of Hepatitis B was a cross-disciplinary clinical course featuring speakers and panelists from the American Academy of Dermatology (AAD), American Society of Clinical Oncology (ASCO), American College of Rheumatology (ACR), and National Cancer Institute (NCI). Our joint efforts and persistence as an organization in this area was instrumental in the Food and Drug Administrations (FDA) announcement of the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab).

Digestive Disease Week

DDW is sponsored through the partnership of four leading medical societies focused on the digestive system: AASLD, American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE), and The Society for Surgery of the Alimentary Tract (SSAT). As a sponsoring society with a strong presence and an excellent liver and biliary tract education program, AASLD's successful liver-specific sessions include state-of-the-art presentations, clinical symposia, presidential plenaries, research fora, poster presentations, and a Research Highlights session devoted to Hepatology: The Year in Review.

LiverLearning®

As AASLD's official eLearning portal, LiverLearning® has continued to grow in both content and reputation. In 2013, AASLD launched the LiverLearning® mobile application for Apple and Android, allowing the user to view all webcasts and ePosters available on the portal in a mobile format. LiverLearning® now has hundreds of hours of webcasts, over 6,000 abstracts, and over 2,300 ePosters.



AASLD Curriculum & Training (ACT)

ACT-FIRST

AASLD in collaboration with the American College of Physicians (ACP), Centers for Disease Control (CDC), U.S. Department of Veterans Affairs (VA), and Project ECHO began development of a hepatology curriculum in 2013. The program will provide training (didactic) in Hepatology to front-line providers, with the ultimate goal of improving the care of patients with liver disease. The first two modules being developed are on Hepatitis B and C and will launch at the ACP Annual Meeting.

ACT-on-HCV

This interactive program provides strategies and mentoring for managing HCV and is designed to increase the confidence and competence of healthcare professionals new to providing care for patients with HCV. It includes interactive online CME/CE-certified modules and experiential component which includes logging direct clinical experiences. The five modules were reviewed and monthly webinars with case-based discussions were offered to participants.

Collaboration

To expand our impact on education, research, training and therapy of liver disease AASLD collaborates with related societies and organizations. AASLD actively seeks cooperative ventures with appropriate national, regional and international organizations in order to pursue projects of mutual interest. These interactions are meant to be mutually beneficial and increase our ability to fulfill our vision and mission of treating and curing liver disease.

2013 collaborative efforts included:

Alpha-1 Foundation AASLD/Alpha-1 Foundation Liver Scholar Award	American Subspecialty Professors (ASP) Centers for Disease Control (CDC) ACT-First
American Board of Internal Medicine (ABIM) Competency-based Curriculum The Liver Meeting® Competency Workshop	Centers for Medicare & Medicaid Services (CMS) EASL Co-sponsored the AASLD/EASL Clinical Research Single Topic Conference on <i>Portal Hypertension and Variceal Hemorrhage</i>
American College of Gastroenterology (ACG) Practice Guidelines Training Directors Workshop	Food and Drug Administration (FDA) Endorsed the FDA Drug Induced Liver Injury program on <i>Detecting and Evaluating Drug-Induced Liver Injury and Dysfunction: What's Normal ? What's Not? What Should We Do About It?</i> Co-sponsored the AASLD/ FDA Workshop on <i>Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease</i>
American College of Physicians (ACP) Subspecialty Advisory Group on Socioeconomic Affairs Council of Subspecialty Societies ACT-First The Liver Meeting®	International Association for the Study of the Liver Co-sponsored the AASLD/IASL Symposium
American Gastroenterological Association (AGA) Digestive Disease Week Training Directors Workshop	International Liver Disease Associations African Association for the Study of Liver Disease Asian-Pacific Association for the Study of the Liver European Association for the Study of the Liver International Liver Cancer Association International Association for the Study of the Liver Latin-American Association for the Study of the Liver World Gastroenterology Association
American Liver Foundation (ALF) Combined awards selection committee	
American Medical Association Physicians Consortium for Practice Improvement (PCPI)	
American Society of Clinical Oncology (ASCO) GI Cancers Symposium, content advisor	
American Society of Gastrointestinal Endoscopy (ASGE) Digestive Disease Week The Liver Meeting®	

International Liver Transplantation Society (ILTS) The Liver Meeting® <i>Liver Transplantation Journal</i>
National Institutes of Health (NIH) North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) The Liver Meeting® Digestive Disease Week—Clinical Symposium on <i>Liver Manifestations of Intestinal Disease in Children</i>
Project ECHO ACT-First
PSC Partners Seeking a Cure PSC Abstract Award
Society for Surgery of the Alimentary Tract (SSAT) Digestive Disease Week
United Network for Organ Sharing (UNOS)
Veterans Administration (VA) ACT-First

Journals



HEPATOLOGY
The premier publication in the field of liver disease, **HEPATOLOGY** publishes original, peer-reviewed articles concerning all aspects of liver structure, function, and disease. Each month, the distinguished editorial board monitors and selects only the best

articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism.

2013 EDITOR: Michael H. Nathanson, MD



LIVER TRANSPLANTATION
Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. This journal delivers current, peer-reviewed articles on

surgical techniques, clinical investigations and drug research—the information necessary to keep abreast of this evolving specialty.

2013 EDITORS: John R. Lake, MD
John P. Roberts, MD



CLINICAL LIVER DISEASE (CLD)
CLD is the latest online learning resource of AASLD. Clinical in

focus, CLD blends text, audio, video, webinars, and other interactive content into education interventions launched every two months. These interventions are designed for any physician or healthcare provider caring for a patient with liver disease.

2013 EDITOR: Michael R. Lucey, MD

CLINICAL PRACTICE GUIDELINES

AASLD develops clinical practice guidelines supported by a high level of scientific evidence to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Where published information is insufficient to make strongly evidence-based recommendations, the state of the art of current practice based on descriptive reports and expert opinions are published as position papers. AASLD has published 18 practice guidelines and two position papers which are updated regularly at www.aasld.org and rewritten and published in the society's journals every five years.

In recent years, AASLD has partnered with several societies to develop practice guidelines under the oversight of the Practice Guidelines Committee. Letters of Agreement define the terms of collaboration which include representation on the writing group, review of each draft, and concurrent publication in each society's journal. Related societies expressing interest in endorsing AASLD guidelines are provided early drafts for review and approval.

PUBLISHED

- Long-Term Management of the Successful Adult Liver Transplant (in collaboration with the American Society of Transplantation)
- Long Term Medical Management of the Pediatric Patient following Liver Transplantation (in collaboration with the American Society of Transplantation and endorsement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition)
- Update of Management of Adult Patients with Ascites due to Cirrhosis
- Evaluation of the Adult Patient for Liver Transplantation (in collaboration with the American Society of Transplantation)

IN DEVELOPMENT

- Evaluation of the Pediatric Patient for Liver Transplantation (in collaboration with the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the American Society of Transplantation)
- Diagnosis and Management of Hepatic Encephalopathy (in collaboration with the European Association for the Study of Liver)

Online Expert Advice for Clinicians Treating Hepatitis C

AASLD and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society-USA (IAS-USA), established the framework and writing panel to offer up-to-date guidance for the treatment of hepatitis C virus (HCV) infection. The initial recommendations were completed following Food and Drug Administration (FDA) approval of two direct-acting antivirals for the treatment of hepatitis C in late 2013. The Recommendations for Testing, Managing and Treating HCV were published on a new website, www.HCVguidelines.org, in January 2014.

In contrast with traditional Practice Guidelines, this web-based guidance was developed rapidly and will be revised regularly to keep pace with improved diagnostic tools and new drug options as they meet FDA approval. Recent changes in HCV testing guidelines have led to the diagnosis of increasing numbers of patients who were previously unaware of their infection. The guidance provided through www.HCVguidelines.org comes at a critical time as more and more of these patients seek treatment that has the potential to effectively ‘cure’ them.

The website is accessible to all practitioners who treat patients with liver disease and provides expert advice about how to best use the next generation of direct-acting antivirals and other treatment options. A panel of 26 hepatologists and infectious diseases specialists and a patient advocate developed the evidence-based, consensus recommendations.

The initial guidance includes:

- HCV Testing and Linkage To Care
- Recommendations for Initial Treatment of HCV Infection in Patients Starting Treatment
- Retreatment in Persons in Whom Prior Therapy Has Failed
- Unique Patient Populations

Additional sections, including Who Should Be Treated and Monitoring Patients on HCV Therapy, will be included in subsequent updates.

It is estimated that between 3 and 4 million Americans are infected with HCV and have chronic liver disease as a result. The most recent generation of direct-acting antivirals has the potential to cure most patients with HCV. However, the rapid pace of drug development has left medical providers and insurance companies unsure what the optimal treatments are. The guidance provided through www.HCVguidelines.org will assist clinicians in using these and other treatments in the care of their patients.

Funding for the project is provided by AASLD and IDSA.

EFFECT

The public policy agenda of the American Association for the Study of Liver Diseases (AASLD) in 2013 continued to grow and evolve. AASLD’s growth reflects the growth in the role of the government in the fields of medical practice and medical research. Gone are the days of AASLD members focused on their labs, or teaching or practice solely. AASLD has been a significant and growing participant as key decisions are made at in both the legislative and executive branches of the government.

A number of seminal events in recent years—the passage of the Affordable Care Act and the Budget Control Act, for example—have greatly enhanced the focus on health care issues in Washington, in general. And, as AASLD members know, the impact of liver disease on the health of Americans has never been greater. Fortunately, the quality of treatments has been improving steadily, particularly with regard to viral hepatitis. AASLD’s mission in this area is to ensure that public policies keep pace with the rapid scientific advancements and understanding that is occurring.

RESEARCH

Strong advocacy for increased funding for research is always one of the primary foci of AASLD during Liver Capitol Hill Day (see below), as well as throughout the year. The level of appropriated funds for the National Institutes of Health (NIH), the Department of Veteran Affairs (DVA) and the Agency for Healthcare Research and Quality (AHRQ) research is critically important to AASLD members—and to their patients.

2013 proved to be an incredibly challenging year on the research funding side, as liver research became “collateral damage” in the budget wars that we afflicting the Congress at the time. As a result of provision in the Budget Control Act of 2012 and Congress’s inability to reach agreement on funding levels, a process known as sequestration took effect which resulted in a 5.1 percent reduction of all domestic discretionary spending on March 1, 2013. Fortunately, after the government shutdown on October 1 was resolved, cooler heads prevailed and in the FY14 appropriations bill fully 2/3 of the reduction was restored.

The goals associated with AASLD’s public policy mission in research are too numerous to detail here. We continue to pursue these, and all of our public policy priorities, in a reasonable and measured way based upon promoting the strongest science we are able to provide.

PATIENT CARE

The Centers for Disease Control and Prevention (CDC) in Atlanta is the home of the Division of Viral Hepatitis. Funding for this important agency—the only element of CDC that currently addresses liver disease in any way—has been consistently inadequate. AASLD has worked with Congress and the administration and continues to seek additional funding to assure that CDC is able to bring its prevention and treatment messages about viral hepatitis to all fifty states.

Hepatitis C screening for persons born between 1945 and 1965 is a strong recommendation of the CDC. However, the US Preventive Services Task Force (USPSTF) reviewed the evidence and gave such screening a C rating, which is critical because an A or B rating would mandate that it be considered an “essential health benefit” and would prohibit charging

co-pays to public and private insurance beneficiaries. AASLD, along with our partners in the patient advocacy community, presented reams of evidence to prove the value of the screening. In an almost unprecedented move, USPSTF reversed itself and gave the screening a B rating, greatly enhancing the potential for identifying hepatitis C patients earlier in their disease.

In addition, with the implementation of the Affordable Healthcare Act (ACA) continuing to move ahead, AASLD has increased its involvement substantially in the development of quality measures for physicians treating patients with liver disease. This complex process will have an important and growing role in the future in assuring access to care for patients and adequate reimbursement for providers.

We have also continued to work closely with some of the leading officials at the U.S. Food and Drug Administration to assure that this important regulatory agency is actively engaged in the latest advances in treating liver disease. Meetings have occurred on a variety of topics including, most prominently this year, dealing with reactivation of hepatitis B.

LIVER CAPITOL HILL DAY

In 2013, AASLD sponsored its Fifth Annual Liver Capitol Hill Day (LCHD) bringing together AASLD member-physicians, some of their patients, and representatives of six patient advocacy organizations in a day of meetings with Senate and House members and staff. The roughly 60 participants involved in the day advocated for increased research funding and better patient care. They conducted more than 85 meetings on Capitol Hill, working in teams that combined patients and physicians to relate both the personal impact of liver diseases and the scientific opportunities to address it.

We anticipate that our program will be continued and expanded in March of 2014, when AASLD members, their patients and our partners from patient advocacy

organizations return to Capitol Hill for the Sixth Annual LCHD. The Association has made a strong commitment to keeping liver front and center as Congress faces tough budget and policy decisions. A significant part of this mission is to explain the long-term cost avoidance associated with diagnosing and treating all liver diseases—including viral hepatitis—at the earliest possible time. And the success of that effort depends on investing in research now.

FEDERAL AGENCY DAY

For the last six years, AASLD has undertaken a significant effort to expand its involvement with a broader spectrum of government agencies. Again in 2013, more than a dozen members of the AASLD Governing Board and committee leadership came to Washington DC to conduct meetings throughout the greater Washington DC area.

One team of AASLD leaders went to the NIH and met with the leadership of four different institutes which have significant liver research portfolios. The other team of leaders met with officials from the Office of the Assistant Secretary for Health in the Department of Health and Human Services; the Veterans Health Administration in the VA; and the Food and Drug Administration (FDA). In 2014, we plan to build on this effort visiting agencies that will be most beneficial to AASLD members and where the greatest opportunities for advancement exist.



THE AASLD LIVER RESEARCH FUND

KNOWLEDGE | PRACTICE | CURE

Thank You for Your Support 100% OF YOUR DONATION IS USED TO SUPPORT LIVER RESEARCH

INDIVIDUAL DONORS

Anonymous (10)
Manal F. Abdelmalek, MD, MPH
Joseph M. Alcorn, MD
Mohammed S. Anwer, PhD, DMVH
Shahid Aziz, DO
Jasmohan Bajaj, MD
Graham F. Barnard, MD, PhD
Oscar Alfredo Beltran, MD
Paul D Berk, MD
Thomas Boyer, MD
Carol L. Brosgart, MD
Sheila Charleston Chuhan Chung, MD
Stanley Martin Cohen, MD
Scott Cotler, MD
Son T. Do, MD
Adrian M. Di Bisceglie, MD, FACP
Kimberly Farrell
J. Gregory Fitz, MD
Kristen Gengaro
Regino Gonzalez-Peralta, MD
Stuart C Gordon, MD
Norman D Grace, MD
Joseph Hoffman, MD
Nadeem Hussain, MD
Ravi Jhaveri, MD
Tsunehisa Kawasaki, MD, PhD
Andrew Keaveny, MD
M. Farooq Khokhar, MD
W Ray Kim, MD
Ayman A. Koteish, MD
Edward L. Krawitt, MD
Gerd Kullak-Ublick, MD
Anne M. Larson, MD
Patricia S. Latham, MD
Jay Lefkowitz, MD
Zhiping Li, MD
Anna Suk-Fong Lok, MD
Rohit Loomba, MD
Michael R. Lucey, MD
Jorge Marrero, MD
Mack C. Mitchell, MD
Omar Massoud, MD
Nahum Méndez Sánchez, MD, PhD
Ethan D. Miller, MD
Timothy Morgan, MD
Jane & David Novick, MD
Lisa Marie Nyberg, MD, MPH
Joseph Odin, MD, PhD
Robert K. Ockner, MD

Marco A. Olivera-Martinez, MD
George Ostapowicz, Bmed, MD, FRACP
Stephen Chris Pappas, MD
Alexandra E. Read, MD
Ricardo Rebuffi
Gautham Reddy, MD
Mary Rinella, MD
Philip Rosenthal, MD
Richard A. Schreiber, MD
David Shapiro, MD
Seal Financial Group
Leonard B. Seeff, MD
Benjamin L. Schneider, MD
William Sloan, MD
Louis Wong Kee Song, MD
Frederick J. Suchy, MD
Yasukiyo Sumino, MD, PhD
Anthony S. Tavill, MD
Brent A Tetri, MD
Emmanuel Thomas, MD, PhD
Natalie Torok, MD
Kymberly Watt, MD
Francis R. Weiner, MD
Vincent Wong, MD
Kentaro Yoshioka, MD, PhD
Samir Zakhari, PhD
Joe Louis Loquinario Zimmerman
Stephen D. Zucker, MD
In Honor of Laurie Blendis
Dirk J. Van Leeuwen, MD, PhD
In Honor of Anne Borhart
Debra Diedrick
Karen & Mark Ostrander
Trudy Ann Jurs
In Honor of Sherrie Cathcart
David J. Reich, MD, FACS
In Honor of Tren Duevel
Sarah Catherine Beasley
Hannah E. Schlei
In Honor of Tanner Hickman
Anonymous
Jason & Myriah Baker and Family
Eric Walker
In Honor of Marshall Jacobson
Anonymous

In Honor of Jack Levin
Michael L. Schilsky, MD
In Honor of Libia Lopez
Danny & Trisha Rey and Family
In Honor of Franklin Rogers
Anonymous
In Honor of Ramaraju Vijayakrishna
Gopal A. Ramaraju, MD
In Memory of Steven Amelotte
Marilyn & George Miller
In Memory of William Trenton Bradley, Jr.
Linda & Steve Kish
In Memory of Mike Browne
Anonymous
In Memory of Phyllis Casey
Barbara Carmack
Irene & Ralph Darbyshire
Tom & Sharon McGillivray
Michele Hope & Harry Rosenfeld
Brunhilde & Lewis O'Brien
Irene & Jerry O'Brien
Nancy Swanton & Brent Petrie
Bureau of Ocean Energy Management
In Memory of Judith Ann Cash
Anonymous
In Memory of Daniel C. Cockren
Julia & Ryan Merrill
In Memory of Kathleen M. Curry
Anonymous
Russ & Jane Anderson
Nancy Camfora
Ruth & William Carroll
John Cohen, MD and the Staff of Newton Wellesley Pediatrics
Susan M. Curley
Roberta M. Dee
Jane Dufault
Courtney Ellard & Shaun Wason
Janice & Robert Femino
Karen Gibson
Tiffany & Rob Giglio and Girls

Florence & Edward Gorny
Bev & Dick Hagen
Andrea & John Hockridge
Meagan Hockridge
Sandra & Robert Jones
James S. Kavannah
The Keyo Family
Mr. & Mrs. Jack McCarthy
Arlene & Stephen O'Brien
Emma O'Leary
Steven & Jennifer Pratt Family
Linda & James Rogers
The Sarnowitz Family
Priscilla Saucier
Shelley J. Shuman
Dana & Michael Silveira
Ann & Lyle Staab
Joanne & William T. Sweeney
Doreen & Richard Tremaine
Bryan, Lindsay, Cameron & Cali Weber
Scott Weber
Teri & Bob Weber
In Memory of William J. Curry
Russ & Jane Anderson
Marcia & Bruce Basarab
Diana & Douglas A. Berthiaume
Marie & Paul Broderick
Mary & Eugene Cassis
Bev & Dick Hagen
Barbara & E. Neil Hodgnerney
Steven & Jennifer Pratt Family
Joy Robinson
The Sarnowitz Family
Frank & Pattie Sorrentino
Ann & Lyle Staab
Phil & Kathie Taymor
Doreen & Richard Tremaine
Terri Ann Yaz
MFS—GIS
The SEC Institute, Inc.

In Memory of Annie Endriulaitis
Irene Harbuziuk DeWolf
Ben Skvirblys
In Memory of John Lee Gibbons
Anonymous
In Memory of James Edward (Bud) Goodman
Carol Rae & Paul Moore
In Memory of Tedine Greenwald
Celeste Nugent Dolan
In Memory of Gina Heindl
Howard & Iris Helis
In Memory of Michael Kirt Henderson
Judy Henderson
In Memory of Paul Jarman Jr.
Frank & Sharon Dowhan
In Memory of Marshall Kaplan, MD
Lawrence S. Friedman, MD
In Memory of Emmet Keeffe, MD
Walid Ayoub, MD
In Memory of Allison Copeland King
Phyllis & PD Nicaise
In Memory of Patricia Kowanick
Alexander T. Lalos, MD
In Memory of Ronald Krieger
Tim Krieger
In Memory of James Laurie
Kathleen & Lawrence Wisinski
In Memory of Dr. Eric Lemmer
Anonymous
In Memory of Edward S. Levine
The Beach Bowlers
In Memory of John Mangialetto
Jack & Sandra Mackston
In Memory of Clara Newton
Cara Nina Newton
In Memory of Kenichi Okabe
Yumiko & Scott Residor
In Memory of Carlos Y. Ortiz
Mia Estella

In Memory of Cindy Raiford
Kathleen M. Meskill
Shirley Nasoff
Robert C. Raiford
In Memory of Victor Rothstein
Maria & Kenneth D. Rothstein, MD
In Memory of Teresa Savo
Susan Blomster
John & Betse Courtmanche
Geri Diorio & Mark Edwards
Ann & Ron Petrillo
In Memory of Kimberly Skadan
Donna Norsen
In Memory of Mark J. Vierling
Drs. Donna & John Vierling
In Memory of Michael Vieau
Rita Mae Marsh
Mary Lou McGarry
Anna & Donald Turtenwald
Ken & Sue Wagner
Donna & Charles Wood
Jody & David Rymaszewski
In Memory of Cecilia Vitale
Teresa Battiatia
Mr. & Mrs. Peter Bongiorno
Mr. & Mrs. Nino Domingo
Mr. & Mrs. Peter Domingo
Mr. & Mrs. Peter Domingo
Matilda & Angelo Illuzzi
Mr. & Mrs. Salvatore Sereno
Matilda & Ernest Tarmin
Josephine Valenti
Dino A. Vitale
In Memory of Julie Ann Drayer Whyte
Anonymous (3)
Kumar Bala
Bonny Bender
Francis Ann Cummings
Monica DiCorpo
Troy Gibson
Sally Kruger
Sarah Mueller
Ian Robbins
Fede & Brad Rodriguez
Amy Stagl

In Memory of J.R. Wilkins
Kim, Patty & Joan
In Memory of J. Richard (Dickie) Williams
Jackie & Al Meyers
In Memory of Wanda Wentworth
Catharine & James Bell
Peg Lloyd & Cindy Gladhill
Charleen Griemsman & Glenn Luedtke
Janet & Harry Faust
Terry and Clay Kotara
Patti Quinn and Melinda Wright
On Behalf of James Browning
Thomas Kraynak
On Behalf of Dr. Ana Corregidor
Anonymous
On Behalf of Patricia Magreta
Anonymous
In Support of the Dr. Edmund J. Bini Travel Award
Naga Chalasani, MD
Kyong-Mi Chang, MD
Ramsey Cheung, MD
Samuel B. Ho, MD
Timothy R. Morgan, MD
Saray Stancic, MD
Teresa Battiatia
Andrew Talal, MD, MPH
Craig T. Tenner, MD
Teresa L. Wright, MD
Peiyang Xiao, MD
In Support of the Professor Margit Hamosh Travel Award
Tamar H. Taddei, MD
LEGACY SOCIETY
The Estate of John Hunter

WWW.AASLD.ORG/DONATE














Statement of Activities and Change in Net Assets for the Year Ended December 31, 2012 With Summarized Financial Information For 2011

Revenue 2012

Annual Meeting	\$ 6,668,577
Awards & Grants	\$ 1,196,975
Professional Relations, Fundraising, & Other	\$ 104,587
Meetings & Education	\$ 608,148
Publications	\$ 2,329,996
Rental Income	\$ 225,678
Membership	\$ 1,172,238



Assets

CURRENT ASSETS

	2012	2011
Cash and cash equivalents	\$6,480,934	\$ 7,424,778
Investments—Reserve and Endowments	24,535,745	20,550,452
Investments—Liver Research Fund	6,721,312	5,751,327
Contributions receivable, current portion	829,405	1,153,575
Accounts receivable	785,510	610,288
Prepaid expenses	212,821	95,913
Total current assets	39,565,727	35,586,333

FIXED ASSETS

Office condominium	8,081,872	8,081,872
Furniture and equipment	444,167	412,145
Less: Accumulated depreciation and amortization	8,526,039	8,494,017
	(1,650,653)	(1,371,757)
Net fixed assets	6,875,386	7,122,260


OTHER ASSETS

Contributions receivable, net of current portion	132,225	652,640
Deferred financing cost, net of accumulated amortization of \$30,358	111,575	116,306
Deferred compensation investments	159,673	103,362
Deposits	83,978	89,673
Total other assets	487,451	961,981

Total assets	\$46,928,564	\$43,670,574
---------------------	---------------------	---------------------

Expenses 2012

Annual Meeting	\$ 3,042,586
Awards & Grants	\$ 2,319,234
Communications	\$ 528,631
Meetings & Education	\$ 1,623,760
Professional Relations	\$ 219,278
Publications	\$ 1,499,507
Leadership, IT & F&A	\$ 1,672,856
FR/Liver Research Fund	\$ 226,148
Membership	\$ 921,921



Liabilities and net assets

CURRENT LIABILITIES

	2012	2011
Current portion of notes payable	\$161,299	\$163,346
Current portion of bonds payable	100,000	100,000
Accounts payable and accrued expenses	1,089,304	1,658,960
Deferred revenue:		
Membership dues	552,040	718,058
Meeting registrations and exhibits	6,480	37,705
Grants and awards payable	1,433,045	1,226,657
Total current liabilities	3,342,168	3,904,726

LONG-TERM LIABILITIES

Notes payable, net of current portion	3,425,907	3,587,205
Bonds payable, net of current portion	3,300,000	3,400,000
Interest rate swap obligation	2,446,042	2,461,185
Deferred compensation liability	159,673	103,362
Total long term liabilities	9,331,622	9,551,752
Total liabilities	12,673,790	13,456,478

NET ASSETS

Unrestricted		
Undesignated	18,033,601	16,084,209
Board designated	8,235,928	5,887,742
Total unrestricted	26,269,529	21,971,951
Temporarily restricted	3,923,395	4,180,295
Permanently restricted	4,061,850	4,061,850
Total net assets	34,254,774	30,214,096

Total liabilities and net assets	\$46,928,564	\$43,670,574
---	---------------------	---------------------

Revenue

Annual Meeting	\$6,456,077	\$212,500	-	\$6,668,577	\$6,703,768
Meetings and Education	608,148	-	-	608,148	716,515
Membership Dues	1,172,238	-	-	1,172,238	1,137,657
Professional Relations	35,000	10,000	-	45,000	26,530
Publications, Hepatology and Liver Transplantation Journals	2,329,996	-	-	2,329,996	2,265,291
Research and Fellowship Awards	150,000	1,046,975	-	1,196,975	1,834,231
Rental income	225,678	-	-	225,678	188,970
In kind contribution	14,500	-	-	14,500	6,900
Communications	-	-	-	-	50,000
Fundraising Campaign/Liver Research	44,611	-	-	44,611	56,916
Other	476	-	-	476	900
Net assets released from donor restrictions	2,092,259	(2,092,259)	-	-	-
Total revenue	13,128,983	(822,784)	-	12,306,199	12,987,678

Expenses

Program Services:					
Annual Meeting	3,042,586	-	-	3,042,586	3,051,942
Professional Relations	219,278	-	-	219,278	202,498
Publication Journals	1,499,507	-	-	1,499,507	1,600,360
Communications	263,206	-	-	263,206	299,205
Research and Fellowship Awards	2,319,234	-	-	2,319,234	2,080,464
Meetings and Education	1,623,760	-	-	1,623,760	1,359,221
Clinical and Public Policies	265,425	-	-	265,425	248,592
Membership Development and Website	921,921	-	-	921,921	794,913
Total program services	10,154,917	-	-	10,154,917	9,637,195
Supporting Services:					
Governance, Executive and Administration	1,672,856	-	-	1,672,856	1,375,362
Fundraising	226,148	-	-	226,148	205,113
Total supporting services	1,899,004	-	-	1,899,004	1,580,475
Total expenses	12,053,921	-	-	12,053,921	11,217,670
Change in net assets before other items	1,075,062	(822,784)	-	252,278	1,770,008

Other Items

Investment (loss) income	3,207,372	565,844	-	3,773,256	(281,553)
Unrealized gain (loss) on interest rate swap obligation	15,144	-	-	15,144	(1,019,544)
Change in net assets	4,297,578	(256,900)	-	4,040,678	468,911
Net assets at beginning of year	21,971,951	4,180,295	4,061,850	30,214,096	29,745,185
Net assets at end of year	\$26,269,529	\$3,923,395	\$4,061,850	\$34,254,774	\$30,214,096

Governing Board

2014 AASLD
Governing Board

President

Adrian M. Di Bisceglie, MD, FACP
Saint Louis University
St. Louis, MO

President-Elect

Gyongyi Szabo, MD, PhD
University of Massachusetts
Worcester, MA

Past-President

J. Gregory Fitz, MD
University of Texas
Southwestern
Dallas, TX

Secretary

Gary L. Davis, MD
Baylor University
Medical Center
Dallas, TX

Treasurer

W. Ray Kim, MD
Stanford University
Stanford, CA

Councilors

Keith D. Lindor, MD
Arizona State University
Phoenix, AZ

Anna Suk-Fong Lok, MD
University of Michigan
Ann Arbor, MI

Ronald J. Sokol, MD
University of Colorado
Aurora, CO

Councilors-at-Large

Raymond T. Chung, MD
Massachusetts General Hospital
Boston, MA

Susan Orloff, MD
Oregon Health and
Science University
Portland, OR

K. Rajender Reddy, MD
University of Pennsylvania
Philadelphia, PA

2013 AASLD
Governing Board

President

J. Gregory Fitz, MD
University of Texas
Southwestern
Dallas, TX

President-Elect

Adrian M. Di Bisceglie, MD, FACP
Saint Louis University
St. Louis, MO

Past-President

Guadalupe Garcia-Tsao, MD
Yale University
New Haven, CT

Secretary

Gary L. Davis, MD
Baylor University
Medical Center
Dallas, TX

Treasurer

Donald M. Jensen, MD
University of Chicago
Chicago, IL

Councilors

Gyongyi Szabo, MD, PhD
University of Massachusetts
Worcester, MA

Keith D. Lindor, MD
Arizona State University
Phoenix, AZ

Anna Suk-Fong Lok, MD
University of Michigan
Ann Arbor, MI

Councilors-at-Large

Norah Terrault, MD, MPH
University of California,
San Francisco
San Francisco, CA

Raymond T. Chung, MD
Massachusetts General Hospital
Boston, MA

Susan Orloff, MD
Oregon Health and
Science University
Portland, OR

2013 AASLD
Committee Chairs

Annual Meeting
Education Committee

Rebecca G. Wells, MD

Basic Research
Committee

Mark J. Czaja, MD

Clinical Research
Committee

Marc G. Ghany, MD

Development Committee

W. Ray Kim, MD

Education Oversight
Committee

Gary L. Davis, MD

Ethics Committee

Adrian Reuben, MBBS, FRCP, FACP

Federal Agencies Liaison
Committee

CHAIR
Laurie D. DeLeve, MD, PhD

Finance Committee

CHAIR
Lynt B. Johnson, MD, MBA

Hepatology Associates
Committee

CHAIR
Joy A. Peter, RN, BSN

Journals Publication
Committee

CHAIR
Theo Heller, MD

Membership &
Mentorship Committee

CHAIR
Steven K. Herrine, MD

Nominating Committee

CHAIR
Guadalupe Garcia-Tsao, MD

Practice Guidelines
Committee

Jayant A. Talwalkar, MD, MPH

Program Evaluation
Committee

Mary E. Rinella, MD

Public and Clinical Policy
Committee

Nancy Reau, MD

Research Awards
Committee

Steven Lidofsky, MD, PhD

Research Awards
Committee

Linda Greenbaum, MD

Scientific Program
Committee

CHAIR
J. Gregory Fitz, MD

Surgery and Liver
Transplantation
Committee

Kenneth D. Chavin, MD, PhD

Training and Workforce
Committee

Bruce A. Luxon, MD, PhD

Past Presidents

2013

J. Gregory Fitz, MD

2012

Guadalupe Garcia-Tsao, MD

2011

T. Jake Liang, MD

2010

Arun J. Sanyal, MD

2009

Scott L. Friedman, MD

2008

Arthur J. McCullough, MD

2007

Gregory J. Gores, MD

2006

John M. Vierling, MD, FACP

2005

Teresa L. Wright, MD

2004

Bruce R. Bacon, MD

2003

Frederick J. Suchy, MD

2002

Thomas D. Boyer, MD

2001

Eugene R. Schiff, MD

2000

William F. Balistreri, MD

1999

Joseph R. Bloomer, MD

1998

Neil Kaplowitz, MD

1997

Nicholas F. LaRusso, MD

1996

Anthony S. Tavill, MD

1995

D. Montgomery Bissell, MD

1994

John L. Gollan, MD, PhD

1993

Esteban Mezey, MD

1992

Jay H. Hoofnagle, MD

1991

Michael F. Sorrell, MD

1990

Roger Lester, MD

1989

Paul D. Berk, MD

1988

David H. Van Thiel, MD

1987

J. Donald Ostrow, MD

1986

Marcus A. Rothschild, MD

1985

Alan F. Hofmann, MD

1984

Robert K. Ockner, MD

1983

E. Lee Forker, MD

1982

Willis C. Maddrey, MD

1981

Steven Schenker, MD

1980

James L. Boyer, MD

1979

Harold J. Fallon, MD

1978

Robert Zeppa, MD

1977

Fenton Schaffner, MD

1976

Irwin M. Arias, MD

1975

William H. J. Summerskill, MD

1974

John R. Senior, MD

1973

Harold O. Conn, MD

1972

Burton Combes, MD

1971

Allan G. Redeker, MD

1970

Richard C. Britton, MD

1969

Archie H. Baggenstoss, MD

1968

Carroll M. Leevy, MD

1967

Kurt J. Isselbacher, MD

1966

Robert E. Shank, MD

1965

Rudi Schmid, MD, PhD

1964

Telfer B. Reynolds, MD

1963

Hans Popper, MD

1962

Hugh R. Butt, MD, MS

1961

Stanley Hartroft, MD

1960

George J. Gabuzda, MD

1959

Richard B. Capps, MD

1958

Thomas C. Chalmers, MD

1957

Gerald Klatskin, MD

1956

Wade Volwiler, MD

1955

Robert M. Kark, MD

1954

Franklin Hanger, MD

1953

Jesse L. Bollman, PhD

1952

Paul Gyorgy, MD

1951

Frederick W. Hoffbauer, MD

1950

Leon Schiff, MD

AASLD Staff

Executive Division

Sherrie Cathcart, CAE
Executive Director

Heidi Bruce, MBA
Director, Development

Audrey Davis-Owino
Director, Governance and Practice Guidelines

Kristin Hutcherson
Coordinator, Governance

Julia Merrill
Coordinator, Development

Erica Taylor
Executive Administrative Assistant

Administration and Finance

Nellie Sarkissian
Chief Operations Officer

Mark Islam
Controller

Catherine Celestino
Staff Accountant

Aaron Batla
Junior Accountant

Communications and Public Policy

Gregory Bologna, CAE
Chief Communications Officer

Martha Sauchuk
Director, Marketing

Ann Haran
Senior Manager, Publications

Kristin Howard
Manager, Marketing

Karey Martinez
Manager, Publications

Megan Webster
Coordinator, Marketing

Kara Cheatham
Editorial Assistant, Publications

Tazeen Shirazi
Editorial Assistant, Publications

Education and Meetings

Julie Deal
Deputy Executive Director

Janeil Klett
Senior Director, Education

Melissa Parrish, CMP
Director, Meetings and Conferences

Denise Seise
Director, Programs and Professional Services

Edward Pramuk
Director, Online Learning

Akena Better, CMP
Senior Manager, Meetings and Conferences

Allyson Petty
Manager, CME Programs

Anne Wrobel
Manager, CME Programs

Crystal Novas
Coordinator, Meetings and Conferences

IT/Web Services

Paula McGraw
Chief Technology Officer

Chris Dugmore
Director, Data Integrity

Wick Davis
Senior Manager, Website

Roger Riddell
Manager, Website

Member Services

Bette Anne Preston
Senior Director, Member Services

Mary Kostelc
Manager, Member Services

Erica Lowe
Representative, Member Services



AMERICAN ASSOCIATION FOR
THE STUDY OF LIVER DISEASES



1001 North Fairfax Street, Suite 400 | Alexandria, VA 22314
Phone: 703-299-9766 | Fax: 703-299-9622 | www.aasld.org